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Background-—Gap junction channels made of Connexin37 (Cx37) are expressed by aortic endothelial and smooth muscle cells of
hypertensive mice, as well as by the renin-secreting cells of kidneys.
Methods and Results-—To decipher whether Cx37 has any role in hypertension, angiotensin II (Ang II) was infused in normotensive
wild-type and Cx37-deﬁcient mice (Cx37/). After 2 to 4 weeks, the resulting increase in blood pressure was lower in Cx37/
than in wild-type mice, suggesting an alteration in the Ang II response. To investigate this possibility, mice were submitted to a
2-kidney, 1-clip procedure, a renin-dependent model of hypertension. Two weeks after this clipping, Cx37/ mice were
less hypertensive than wild-type mice and, 2 weeks later, their blood pressure had returned to control values, in spite of
abnormally high plasma renin levels. In contrast, Cx37/ and wild-type mice that received N-nitro-L-arginine-methyl-ester, a
renin-independent model of hypertension, featured a similar and sustained increase in blood pressure. The data indicate that
loss of Cx37 selectively altered the Ang II-dependent pathways. Consistent with this conclusion, aortas of Cx37/ mice
featured an increased basal expression of the Ang II type 2 receptors (AT2R), and increased transcripts levels of downstream
signaling proteins, such as Cnksr1 and Ptpn6 (SHP-1). Accordingly, the response of Cx37/ mice aortas to an ex vivo AngII
exposure was altered, since phosphorylation levels of several proteins of the AngII pathway (MLC2, ERK, and AKT) remained
unchanged.
Conclusions-—These ﬁndings provide evidence that Cx37 selectively inﬂuences Ang II signaling, mostly via a modulation of the
expression of the Ang II type 2 receptor. ( J Am Heart Assoc. 2019;8:e010823. DOI: 10.1161/JAHA.118.010823.)
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V ascular gap junctions formed of connexins (Cx)
1 provide
for communications between endothelial cells (EC),
smooth muscle cells (SMC), and renin-secreting cells, which
are required to control blood pressure (BP).2–4 In the
vasculature, EC predominantly express Cx37 and Cx40,5–10
whereas SMC mostly express Cx43 and Cx45,6,11,12 and
renin-secreting cells express Cx40 and Cx37.2,7,9,13–15 Vari-
ous changes in the expression of these proteins have been
documented in different models of vascular alterations,
notably during chronic changes in BP.2–4 Speciﬁcally, Cx43
has been reported to allow for the rapid diffusion of calcium-
dependent contraction waves between SMC, which ultimately
control vasomotor tone,16,17 and we have documented a
prominent role of Cx40 in renin-dependent hyperten-
sion.13,14,18 This protein also interacts with endothelial nitric
oxide synthase (eNOS) to increase the production of NO
which, in turn, promotes the relaxation of SMC.5,19 Both renin-
dependent and -independent models of chronic hypertension
also induce the expression of Cx37 in vascular SMC2,6,9; still
the protein appears dispensable for the physiological control
of renin expression and function.7,14,15,18 Thus, whether and
how Cx37 contributes to control BP remains to be fully
investigated.
To approach this question, we compared wild type (WT)
and Cx37/ mice after (1) an infusion of angiotensin II
(Ang II) via osmotic mini-pumps; (2) induction of a renin-
dependent hypertension, as provided by the 2-kidney, 1-
clip (2K1C) surgical procedure; and (3) induction of a
renin-independent model of hypertension, as provided by
a N-nitro-L-arginine-methyl-ester (L-NAME) treatment. We
further compared the aortas of these animals ex vivo,
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under basal conditions and following an exposure to Ang
II. Here, we show that loss of Cx37 partially protects
mice against the development of Ang II-dependent
hypertension, but not against the hypertension induced
by L-NAME. We further document that the lower increase
in BP of Cx37/ mice in response to Ang II is
associated with increased levels of Ang II type 2 receptors
in their aortas, with selective changes in the transcript
levels of proteins involved in the Ang II signaling, including
SHP-1 and CNKSR1, and with an altered phosphorylation of
downstream targets of this signaling pathway (MLC2, ERK,
and AKT). The data provide direct evidence that Cx37 plays
a crucial, selective role in the control of Ang II-dependent
hypertension.
Methods
The data, analytic methods, and study materials will be
available to other researchers, for purposes of reproducing
the results or replicating the procedure, on request from the
Department of Medicine, Lausanne, Switzerland.
Animals and Surgery
Experiments were performed using 2- to 3-month-old
Cx37/ males (a kind gift from Dr A. Simon),20 and WT
littermate mice, all on a C57BL/6J genetic background.
These mice were generated by breeding heterozygote
Cx37+/ males and females. WT, heterozygous, and
knockout animals were identiﬁed by polymerase chain
reaction of genomic DNA, using the following primers:
forward primer 50-TGCTAGACCAGGTCCAGGAAC-30 and
reverse primer: 50-GATCTCTCGTGGGATCATTG-30 to detect
the Cx37 knockout allele, and reverse primer: 50-
GTCCCTTCGTGCCTTTATCTC-30 to detect the Cx37 WT allele.
All mice were housed in individually ventilated cages, as per
our institutional guidelines. Mouse care, surgery, and
euthanasia procedures were approved by the Centre Hospi-
talier Universitaire Vaudois, and the Cantonal Veterinary
Ofﬁce (Service de la Consommation et des Affaires Veteri-
naires SCAV-EXPANIM, authorization numbers 2832.1 and
3102). All animal experimentation conformed to the Guide
for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication Eighth
Edition, 2011). The 2K1C procedure, which consists of
placing a U-shaped silver clip of 0.12-mm internal diameter
around the left renal artery,6,9,14 was performed in 8- to 10-
week-old WT and Cx37/ mice. Control mice were sham-
operated (no clipping of the renal artery). ALZET osmotic
mini-pumps were loaded with Ang II in 0.9% NaCl, to provide
a daily output of either 0.25 or 1 mg hormone/kg body
weight, and subcutaneously implanted as reported.21,22
Control mice were similarly implanted with pumps containing
only 0.9% NaCl. WT and Cx37/ mice were also treated
with Nx-Nitro-L-arginine methyl ester hydrochloride (L-NAME;
Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), which was
added at the concentration of 500 mg/L to the drinking
water, for 4 weeks.6,12,23
Animal Monitoring
Systolic blood pressure (SBP) was measured on conscious mice
by a noninvasive, computerized tail-cuff method (BP-2000,
Visitech Systems). Mice were pretrained during 7 days, and
thereafter pulse rate and BP were recorded by an automatic
system of cuff inﬂation and deﬂation, over at least 15 days.7,9
At the end of the experience, blood samples (300 lL) were
collected from the tail vein into EDTA-coated tubes. Plasma
was separated by centrifugation at 4°C (8 minutes, 5720g),
and stored at 80°C. Five microliters of plasma diluted in
100 lL 0.9% NaCl were incubated for 90 minutes at 37°C.
Plasma from bilaterally nephrectomized male rats served as
substrate for renin. Plasma renin concentration (PRC) was
determined by measuring the capacity of plasma samples to
generate AngI in the presence of an excess renin substrate. The
generated angiotensin I (ng/mLh1) was determined by
radioimmunoassay (Byk&DiaSorin Diagnostics, Dietzenbach,
Germany).24
Clinical Perspective
What Is New?
• We submitted Connexin37 (Cx37)-null mice to different
models of angiotensin II (Ang II)-dependent and -indepen-
dent hypertension, and document that Cx37 selectively
participates in Ang II-mediated hypertension.
• In the renin-dependent model, Cx37/ mice rapidly
recover a normal blood pressure, in spite of increased
plasma renin levels.
• This response results from an altered expression of proteins
implicated in the Ang II pathway, notably AT2R.
What Are the Clinical Implications?
• Our data suggest the following scenario for the involvement
of vascular Cx37 in the control of Ang II-dependent
hypertension: in the absence of Cx37, increased aortic
levels of AT2R and of downstream targets of the AT2R-
dependent pathway associate to reduce the vasoconstric-
tive effects mediated by Ang II, eventually altering the
development of hypertension.
• Understanding how AT2R is upregulated in the absence of
Cx37 may help in developing new therapeutic tools against
hypertension.
DOI: 10.1161/JAHA.118.010823 Journal of the American Heart Association 2
Cx37 and Hypertension Le Gal et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
RNA and Protein Analysis
Mice were anesthetized with isoﬂurane, euthanized by cervical
dislocation, and then depleted of blood by an intracardiac
perfusion of 5 mL PBS. After PBS washing, aortas and kidneys
were carefully removed, immersed into liquid nitrogen,
reduced to powder, and stored at 80°C. For reverse
transcription polymerase chain reaction analysis, the aortic
and renal powders were homogenized in Tripure Isolation
Reagent (Roche, Switzerland), and total RNA was extracted
according to the manufacturer’s instructions. RNA was
analyzed by real-time quantitative polymerase chain reaction,
using the primers given in Table 1. For Western blots, aortic
powder was homogenized by sonication in lysis buffer
(62.5 mmol/L Tris HCl, 5% SDS, 10 mmol/L EDTA, pH=8).
Protein content was measured using a detergent-compatible
DC protein assay kit (Bio-Rad Laboratories, Reinach BL,
Switzerland). Samples (30 lg) were loaded on a 7% or 10%
polyacrylamide gel, separated by electrophoresis and trans-
ferred onto PVDF membranes (Immobilon-P; Millipore, Volk-
etswil, Switzerland). Membranes were incubated for 1 hour in
PBS or TBS (Tris-Buffered Saline) containing 5% milk and 0.1%
Tween 20 (blocking buffer). The membranes were then
incubated overnight at 4°C with 1 of the following primary
antibodies: rabbit polyclonal antibodies against AT1R (Alo-
mone labs, AAR-011, 1:1000), AT2R (Alomone labs, AAR-012,
1:1000), MLC2 (Cell Signaling, 3672, 1:1000), P-MLC2 (Cell
Signaling, 3674, 1:1000), ERK (Cell Signaling, 4695, 1:1000),
P-ERK (Cell Signaling, 9101, 1:1000), AKT (Cell Signaling,
9272S, 1:1000), Cx40 (Chemicon, AB1726; 1:250), Cx37
(Biotrend Chemikalien, Cx37A11-A; 1:500), Cx43 (Cell
Signaling, 3512S, 1:500) or Cx45 (Millipore, AB1745,
1:500); mouse monoclonal antibodies against eNOS (BD
Biosciences, 610297, 1:500), PeNOS (BD Biosciences,
612392, 1:500), P-AKT (Cell Signaling, 4051, 1:500), and a-
tubulin (Sigma-Aldrich, T5168; 1:2500). The secondary anti-
bodies were horseradish peroxidase–conjugated goat anti-
mouse immunoglobulins (Jackson Immuno research, 63343,
diluted 1:20 000) or goat anti-rabbit immunoglobulins
(Thermo Scientiﬁc, 31460, diluted 1:5000), whichever was
adequate. Bands were developed for enhanced chemilumi-
nescence (Millipore, Immunobilon Western Chemiluminescent
HRP substrate), and visualized using a supercooled CCD
camera (Chemidoc XRS, Bio-Rad Laboratories). Densitometric
analysis was performed using ImageLab Software (3.0.1 Bio-
Rad Laboratories). For immunolabeling, freshly excised kid-
neys and aortas were rapidly frozen and processed for
cryosectioning.5–7,9 Cryostat sections were stained using 1 of
the following antibodies: goat polyclonal antibodies against
renin (R and D, AF4277), rabbit polyclonal against Cx40
(Chemicon, AB1726), Cx37 (Biotrend Chemikalien, Cx37A11-
A) or Cx43 (Cell Signaling, 3512S). All antibodies were diluted
1:100. Primary antibodies were detected using antibodies to
rabbit immunoglobulins labeled with AlexaFluor 488 or to goat
immunoglobulins labeled with AlexaFluor 350 (Invitrogen), all
diluted 1:500.
Statistical Analysis
Values are given as means+SEM in all bar graphs, and as
meansSEM in Table 2. Mean values of different groups
were compared by Student t test or 2-way ANOVA, and the
Table 1. Speciﬁc Primers for qPCR Analysis of Aortas and Kidneys
Gene Sense Primer (50–30) Antisense Primer (50–30)
Renin TCTCTGGGCACTCTTGTTGCTCTG ATACGTCCCATTCAGCACTGAGCC
Agt GTTGGCGCTGAAGGATACAC GACCCAGGTCAAGATGCAGAA
Agtr1a GTCGCACTCAAGCCTGTC CCTGTCACTCCACCTCAG
Agtr1b CGTGCACGGGTGCATTT TAATTGTGCCTGCCAGCCTT
Agtr2 CCAGAGATCTGGTGCAGTTACA TCCCGCATGCACTCCTTAAA
Cnskr1 ACACCCTGACAAGAGTCCCA TACCTGCCTCAACACAGCAG
Ptpn6 TACACCAACGTCTGGAAGGG GGCTGTGGTCAAAGGGAAGA
Enpep GGAAGGCAGAACATCACCCA TGTGTAACCGAGCTCTGACG
Cma1 TGCAGCAGCCCTGAGGA ATCTCTCCAGCTTTGGTGCT
Rgs2 GACTGCGTACCCATGGACAA TCCTTTAAGAGTGTCCGCTTCA
Ace TTACCATAGAGGGCAGCAAG AGGTTCCAGGGGCATACAA
Ace2 GAGGATAAGCCTAAAATCAGCTCTTG TCGGAACAGGAACATTTCGTT
L27 GATCCAAGATCAAGTCGTTTGTG CTGGGTCTCTGAACACATCCT
Mas1 CCTTTGGGAACCTGCATAAC GGATACAGTGTTGCCGTTGC
qPCR indicates quantitative polymerase chain reaction.
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post hoc Tukey test. To compare blood pressure values over
time, we calculated the areas under the systolic blood
pressure curves (AUC), which reﬂect the cumulated blood
pressure responses over the entire, 2-week-long observation
period. The AUC values of different animal groups were then
compared by 2-way ANOVAs, followed by the post hoc Tukey
test. P<0.05 were considered as signiﬁcant. GraphPad Prism
7 was used for statistical analyses.
Table 2. Characteristics of the Mice Subjected to the 2K1C Procedure for 4 Weeks
Mice Groups n SBP (mm Hg) Body Weight (g) Cwi (mg/g) LKi (mg/g) RKi (mg/g)
WT Sham 16 96.51.1 26.20.5 5.20.1 6.50.1 6.90.1
2K1C 19 115.31.5‡ 25.50.5 5.80.2* 5.40.3† 7.70.2*
Cx37/ Sham 14 92.30.8 27.30.6 5.10.1 6.10.2 6.50.2
2K1C 17 97.21.4k 27.90.6§ 5.50.2 5.70.2* 7.60.2†
Values are meanSEM. Cwi indicates cardiac weight index (mg heart weight/g body weight); Cx37, Connexin37; 2K1C, 2 kidney, 1 clip; LKi, left kidney index (mg left kidney weight/g body
weight); n, number of mice; RKi, right kidney index (mg right kidney weight/g body weight); SBP, systolic blood pressure; WT, wild type.
*P≤0.05, †P≤0.01, ‡P≤0.001 vs sham mice.
§P≤0.05, kP≤0.001 vs WT mice given by 2-way ANOVA.
Figure 1. Loss of Cx37/ alters the increase in blood pressure in models of renin-dependent
hypertension. A, WT mice receiving daily 1 mg Ang II/kg body weight displayed a 50% increase in systolic
blood pressure (SBP). Under the same conditions, Cx37/mice displayed a signiﬁcantly lower increase of
SBP. WT NaCl N=5; Cx37/ NaCl, WT Ang II (angiotensin II), Cx37/ Ang II N=6. B, Similar observations
were made in mice receiving daily 0.25 mg Ang II/kg body weight WT NaCl, Cx37/ NaCl N=7; WT Ang II,
Cx37/ Ang II N=8. C, Two weeks after the 2K1C (2-kidney, 1-clip) procedure, Cx37/ mice also
showed a lower increase in SBP than WT controls. WT sham (sham-operated controls) WT 2K1C, N=5;
Cx37/ sham, Cx37/ 2K1C N=6. D, In contrast, both types of mice became similarly hypertensive
after a treatment with L-NAME (N-nitro-L-arginine-methyl-ester); N=6. ***P≤0.001 vs corresponding controls
(NaCl-infused or sham-operated animals); °°°P≤0.001 vs WT mice, as given by 2-way ANOVA of AUC (areas
under the SBP curve). Ang II indicates angiotensin II; Cx37, connexin37; WT, wild type.
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Results
Loss of Cx37 Attenuates the Increase in Blood
Pressure Induced by Ang II
Basal SBP was similar in WT and Cx37/ mice (Figure 1
and Table 2). A systemic, 2-week-long infusion of NaCl did not
alter the SBP of control WT and Cx37/ mice (Figure 1A).
In contrast, the daily infusion of 1 mg Ang II/kg body weight
markedly increased (P<0.001) SBP in both types of animals
(Figure 1A), even though this increase was signiﬁcantly lower
(P<0.001) in Cx37/ than WT mice (Figure 1A). Infusion of
a lower dose of Ang II (0.25 mg/kg body weight) revealed a
comparable difference between the 2 types of mice, in spite
of a modest increase in SBP (Figure 1B).
During the ﬁrst 2 weeks following the 2K1C surgery,
known to induce a renin-dependent hypertension, SBP was
also increased in both WT and Cx37/ mice and, again, this
increase was lower (P<0.001) in the latter than in the former
mice (Figure 1C). In contrast, such a difference was not
observed after an L-NAME treatment, known to induce a renin-
independent hypertension (Figure 1D). The data suggest a
selective role of Cx37 in the control of Ang II-dependent
pathways.
Sustained Clipping of the Renal Artery Did Not
Alter SBP of Cx37/ Mice
Four weeks after the 2K1C surgery, SBP remained signiﬁcantly
higher than control values in WT mice (Table 2 and Figure 2A).
In contrast, SBP of Cx37/ mice had returned to the levels
observed in sham-operated controls (Table 2 and Figure 2A),
documenting that the hypertension observed immediately
after the 2K1C procedure (Figure 1C) was transient. A 4-week-
long, daily infusion of 0.25 mg Ang II/kg body weight also
increased SBP signiﬁcantly less (P<0.001) in Cx37/ than in
WT mice (Figure 2B), whereas an L-NAME treatment of the
same duration had a similar hypertensive effect (P<0.001) in
both types of mice (Figure 2C).
Evaluation of the organs obtained 4 weeks after the 2K1C
surgery revealed the anticipated decrease in the relative
weight index of the clipped kidney, and the associated increase
in the relative weight of the unclipped kidney, in both WT and
Cx37/ mice, demonstrating that the 2K1C procedure
similarly affected these organs in both types of animals
(Table 2). However, the heart weight increased in the hyper-
tensive 2K1C WT mice, but was not affected in Cx37/mice
(Table 2). The data document that, in the absence of Cx37, the
modulation of hypertension because of the 2K1C procedure is
transient, in spite of persistent renal effects of the surgery.
Accordingly, the levels of renin transcripts were similarly
increased over control levels, in the clipped kidneys of both
WT and Cx37/ mice (Figure 3A). Parallel immunostaining
of renin showed that the expression of this hormone
increased in the hypoperfused kidneys of both WT and
Cx37/ 2K1C mice, and decreased in the unclipped,
Figure 2. Cx37/ mice become rapidly nor-
motensive after the 2K1C procedure. A, One month
after the 2K1C surgery, WT mice were signiﬁcantly
hypertensive, compared with their sham-operated
controls, whereas Cx37/ mice featured a con-
trol SBP (systolic blood pressure). WT sham (sham-
operated controls) N=15; Cx37/ sham N=14;
WT 2K1C (2-kidney, 1-clip) N=19; Cx37/ 2K1C
N=17. B, Compared with controls infused with NaCl,
both WT and Cx37/ mice showed a signiﬁcant
increase in SBP after a daily infusion of 0.25 mg Ang
II/kg body weight during 1 month. However, this
increase was signiﬁcantly lower in Cx37/ than
in WT mice. WT NaCl, Cx37/ NaCl N=7; WT Ang
II (angiotensin II); Cx37/ Ang II N=8. C, In
contrast, the mice of these 2 genotypes showed a
similar increase in blood pressure, after a daily
treatment with L-NAME (N-nitro-L-arginine-methyl-
ester, 500 mg/L in the drinking water) for 1 month.
N=6. Results are means+SEM. *P≤0.05 and
***P≤0.001 vs respective control mice;
°°°P≤0.001 vs WT mice, as given by 2-way ANOVA.
Ang II indicates angiotensin II; Cx37, connexin37;
n.s., not signiﬁcant; WT, wild type.
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contralateral kidneys of the very same animals (Figure 3C),
still was higher in the kidneys of Cx37/ than of WT mice.
Consistent with these observations, the concentration of
circulating renin was signiﬁcantly higher in the plasma of
Cx37/ than in WT mice, in both the sham-operated mice
and in the mice that were subjected to the whole 2K1C
procedure (Figure 3B). The data document that, while the
transcriptional expression of renin was similarly modulated by
the 2K1C procedure in the kidneys of WT and Cx37/
mice, the latter animals featured a higher renal content and
plasma secretion of the hormone.
Cx37 Participates in Controling Ang II Signaling in
Aortas
To investigate the mechanism associated with the reduced
effect of Ang II in Cx37/ mice, we studied the
expression of transcripts coding for proteins involved in
Figure 3. Renin expression and secretion are increased by the 2K1C surgery in both WT and Cx37/ mice. A, Four weeks after surgery, the
basal levels of the renin transcript increased in the clipped, hypoperfused kidney of both WT and Cx37/ mice. WT sham (sham-operated
controls) N=14; Cx37/ sham N=13; WT 2K1C N=16; Cx37/ 2K1C N=12. B, The plasmatic concentration of renin (PRC) was also
signiﬁcantly increased in the 2 types of mice. However, Cx37/ mice had basal and 2K1C-induced levels of PRC signiﬁcantly higher than WT
animals. WT sham N=8; Cx37/ sham N=6; WT 2K1C (2-kidney, 1-clip) N=9; Cx37/ 2K1C N=6. Results are means+SEM. *P≤0.05,
***P≤0.001 vs respective control mice; °P≤0.05, °°°P≤0.001 vs WT mice, as given by 2-way ANOVA. C, Renin immunostaining (green) increased
in the hypoperfused left kidney of both WT and Cx37/ mice, while decreasing in their contralateral right kidney, and was higher in Cx37/
than in WT mice. Cx40 (Connexin40). Immunostaining (red) localizes the renin-secreting cells of the afferent arterioles. Bar=50 lm. AngI
indicates angiotensin I; WT, wild type.
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the renin-angiotensin system. The renal levels of the
transcripts coding for the angiotensin-converting enzymes
(ACE and ACE2) were similar in WT and Cx37/ mice,
under both basal conditions and following the 2K1C surgery
(Figure 4). The transcript levels coding for angiotensinogen
and the angiotensin receptors Agtr1a and Agtr1b were also
similarly expressed in the aortas of WT and Cx37/ mice
(Figure 5), and this was also the case for the cognate AT1R
protein (Figure 6A, 6B, and 6D). In contrast, the aortic levels
of Agtr2 transcripts and of the cognate AT2R protein were
higher in Cx37/ than of WT mice (Figures 5 and 6A, 6C,
and 6E). The expression of both ATR1 and ATR2 proteins
was not signiﬁcantly altered in the aortas of Cx37/ mice,
after either the 2K1C surgery or the infusion of Ang II
(Figure 6).
The levels of transcripts coding for downstream proteins
contributing to the AT2R-dependent pathway, including the
AT2R-associated protein CNKSR1 (Cnksr1),25 the AT2R
downstream tyrosine phosphatase SHP-1 (Ptpn6),26 and the
glutamyl aminopeptidase A (Enpep) converting Ang II to Ang
III,27 were also signiﬁcantly higher in the aortas of Cx37/
than of WT mice (Figure 5). In contrast, the mRNA expression
of several other signaling proteins of the Ang II pathway,
including MAS1 (Mas1) the receptor for Ang-(1–7), which is
known to promote vasodilation,28,29 the chymase (Cma1),
which catalyzes the Ang I-cleavaged to Ang II,30 RGS2 (Rgs2),
which negatively regulates the signaling by the G protein
subunits of AT1R,31 and DUSP1 (Dusp1),32 an AT2R-down-
stream phosphatase involved in the AT2R-dependent ERK 1/2
dephosphorylation, was unaltered (Figure 7).
To decipher whether these modulations altered the Ang II-
mediated response, freshly isolated WT and Cx37/ mice
aortas were exposed to 40 lmol/L Ang II during 2 hours. This
exposure increased the phosphorylation levels of the ERK
(Figure 8A), MLC2 (Figure 8B), and AKT proteins (Figure 8C)
in aortas of WT, but not in those of Cx37/ mice.
Collectively, these data document that the regulation of the
Ang II pathway is selectively altered in mice lacking Cx37.
Loss of Cx37 Alters the Basal Expression of
Aortic Cx43 and the Expression of Vascular
Connexins After the 2K1C Surgery
To determine whether the loss of Cx37 altered the expression
of the other vascular connexins, we analyzed aortic extracts
by Western blots. We found that the loss of Cx37 did not
affect the basal, control levels of Cx40 and Cx45, but
signiﬁcantly increased those of Cx43 (Figure 9). Four weeks
after the 2K1C surgery, the levels of Cx37, Cx40, and Cx43
were signiﬁcantly increased in the aortas of WT mice
(Figure 9A through 9C and 9E), whereas those of Cx45 were
Figure 4. The ACEs were similarly expressed in the kidneys of WT and Cx37/ mice. The levels of the
ACE (A) and the ACE2 (B) transcripts were comparable in the hypoperfused kidneys after the 2K1C (2-kidney,
1-clip) surgery and in the sham-operated controls of both WT and Cx37/mice. WT sham N=8; Cx37/
sham N=7; WT 2K1C N=8; Cx37/ 2K1C N=10. Results are means+SEM. Statistical analysis was
performed using 2-way ANOVA. ACE and ACE2 indicates angiotensin-converting enzymes; WT, wild type.
Figure 5. Loss of Cx37 selectively alters the expression of
some Ang II-stimulated signals. The levels of transcripts coding
for Angiotensinogen (Agt), Angiotensin receptor 1a (Agtr1a), and
Angiotensin receptor 1b (Agtr1b) were similar in the aortas of WT
and Cx37/ mice. In contrast, the transcripts coding for
Angiotensin receptor 2 (Agtr2), Connector enhancer of kinase
suppressor of Ras 1 (Cnksr1), SH2 domain-containing tyrosine
phosphatase 2 (Ptpn6), and Glutamyl aminopeptidase A (Enpep),
which all contribute to control the Ang II pathway, were increased
in the aortas of Cx37/ mice. N=9. Results are means+SEM.
*P≤0.05, ***P≤0.001 vs WT mice, as given by t test. Ang II
indicates angiotensin II; Cx37, Connexin37; WT, wild type.
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unchanged (Figure 9D). Under the same conditions, the
aortas of Cx37/ mice shown unchanged levels of Cx40,
and decreased levels of Cx43 and Cx45 (Figure 9B through
9D and 9E). The data document that loss of Cx37 speciﬁcally
affects aortic Cx43, and altered its modulation under
conditions of Ang II-dependent hypertension.
Figure 6. Loss of Cx37 selectively alters the expression of the AT2 receptors in the aortas of Cx37/
mice. A, Immunoﬂuorescence showed a similar staining for AT1R (upper panels) in the aortas of all WT and
Cx37/ mice. In contrast, the staining for AT2R was more intense in the aortas of Cx37/ than in WT
mice. Bar=20 lm. L indicates lumen; M, media. B, Western blot showed that the aortas of WT and Cx37/
 mice expressed similar levels of the AT1R protein. C, In contrast, the basal levels of the AT2R protein
were higher in Cx37/ than in WT mice, and were not increased after the 2K1C surgery. WT sham N=21;
Cx37/ sham N=17; WT 2K1C N=19; Cx37/ 2K1C N=17. D and E, Comparable observations were
made for both AT1R (D) and AT2R (E) in mice infused daily with 1 mg Ang II/kg body weight WT NaCl N=4;
Cx37/ NaCl, Cx37/ Ang II N=3, WT Ang II N=6. Results are means+SEM. °P≤0.05 vs WT mice, as
given by 2-way ANOVA. 2K1C indicates 2-kidney, 1-clip; AngII, angiotensin II; AT1R, Ang II type 1 receptors;
AT2R, Ang II type 2 receptors; Cx37, Connexin37; DAPI, 40,6-diamidino-2-phenylindole; Sham, sham-
operated controls; WT, wild type.
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Loss of Cx37 Does Not Affect the Expression and
Activation of Aortic eNOS
Since Cx37 directly interacts with eNOS,19 we evaluated the
aortic levels of this enzyme. Western blots showed that these
levels were similar in WT and Cx37/ mice, under both
basal conditions, and 4 weeks after the 2K1C procedure
(Figure 10A). Similar observations were made with regard to
the active, phosphorylated form of eNOS (Figure 10B). The
data do not support a participation of the eNOS pathway in
the altered regulation of blood pressure in Cx37/ 2K1C
mice.
Discussion
Previous studies have documented the participation of Cx43,
Cx40, and Cx37 in different models of hypertension.3,5–7,9
While the role of the 2 former connexins has been
understood by multiple studies of different research
groups,2,6,7,9,13,14,33 the involvement of the latter has been
the topic of fewer studies,6–8,15,34 and remains to be fully
validated. Here, we provide direct evidence that Cx37 is
selectively involved in the control of renin-dependent
hypertension, via a mechanism that implicates its control
of several proteins key to the Ang II-dependent pathway.
Thus, loss of Cx37 did not alter the hypertension induced by
a treatment with L-NAME, but reduced the hypertension
induced by either an infusion of Ang II or a 2K1C surgery, 2
conditions that cause a marked renin-dependent hyperten-
sion in control mice.
Our data document that this reduction did not result from a
defective renin or eNOS production in the animals lacking
Cx37, but involved the speciﬁc increased expression of AT2
receptors. In this setting, we observed selective alterations in
the signaling pathway elicited by Ang II. Thus, loss of Cx37 did
Figure 7. Loss of Cx37 does not alter the expression of several
signals involved in the Ang II effects. The levels of transcripts
coding for the chymase (Cma1), which converts Ang I to Ang II,
the Regulator of G-protein signaling 2 (Rgs2), which negatively
regulates AT1R function by modulating its Gaq subunit activity,
the Dual speciﬁcity protein phosphatase 1 (Dusp1), an AT2R-
associated phosphatase that contributes to AT2R-mediated
inactivation of the ERK cascade, and Mas1, the receptor for
Ang-(1–7) that promotes vasodilatation, were similar in the aortas
of WT and Cx37/ mice. WT N=9; Cx37/ N=8. Results are
means+SEM. Statistical analysis was performed using t test. Ang
indicates angiotensin; AT1R, Ang II type 1 receptors; AT2R, Ang II
type 2 receptors; Cx37, Connexin37; WT, wild type.
Figure 8. Loss of Cx37/ alters the activation
of downstream key signaling proteins to the Ang II
signaling pathway. A through C, After a 2-hour
exposure to 40 lmol/L Ang II, the levels of
phosphorylated ERK (A), MLC2 (B), and AKT (C)
increased in the aortas of WT but not of Cx37/
mice. WT Ctl, WT Ang II N=3; Cx37/ Ctl,
Cx37/ Ang II N=5. Results are means+SEM.
*P≤0.05 vs respective control mice and °P≤0.05,
°°P≤0.01 vs WT mice, as given by 2-way ANOVA.
Ang II indicates angiotensin II; Ctl, control; Cx37,
Connexin37; MLC2, myosin light chain 2; WT, wild
type.
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not modify the expression of AT1 receptors, but increased
that of AT2 receptors. Previous studies have shown that AT1
receptors are responsible for the vasoconstrictive effect of
Ang II, which markedly contributes to hypertension,35–39
whereas AT2 receptors antagonize this effect by promoting a
vasodilation that counteracts hypertension.40–44 Indeed, it
was demonstrated that loss of AT2 receptors in mice
resulted in a hypertension that associated with increased
vasopressor response to Ang II.45 Accordingly, a SMC-speciﬁc
overexpression of AT2R in transgenic mice abolished the
vasoconstrictive effect elicited by Ang II.46 These data docu-
ment for the ﬁrst time that the upregulated expression of AT2
receptors observed in Cx37/ mice at least partially
accounts for the mitigated hypertension that these mice
developed when exposed to either an infusion of Ang II or to the
2K1C surgery.
The molecular mechanism whereby increased AT2R
expression may prevent an overt and chronic hypertension
Figure 9. Loss of Cx37 alters the basal expression of aortic Cx43, and protects against the
overexpression of Cx40 and Cx45 after the 2K1C procedure. A, Four weeks after the 2K1C procedure,
Western blots showed a marked increase of Cx37 levels in the aortas of the WT mice that had become
hypertensive. WT sham N=9; Cx37/ sham N=7; WT 2K1C N=9; Cx37/ 2K1C N=11. B, The levels of
Cx40 were also increased in the aortas of WT made hypertensive, but not in Cx37/ mice. WT sham
N=18; Cx37/ sham N=15; WT 2K1C N=16; Cx37/ 2K1C N=14. C, The levels of Cx43 were
enhanced in response to a renin-dependent model of hypertension (WT 2K1C). Cx37-deﬁcient mice also
displayed elevated Cx43 protein levels, which decreased after the 2K1C procedure. WT sham N=17;
Cx37/ sham N=13; WT 2K1C N=14; Cx37/ 2K1C N=17. D, Comparable levels of Cx45 were
evaluated in the aortas of control WT and Cx37/ mice. After the 2K1C surgery, these levels did not
change in the aortas of WT mice, but decreased in those of Cx37/ mice. WT sham N=9; Cx37/
sham N=7; WT 2K1C N=9; Cx37/ 2K1C N=11. Results are means+SEM. *P≤0.05, **P≤0.01 vs
respective control mice; °°P≤0.01, °°°P≤0.001 vs WT mice, as given by 2-way ANOVA. E, After the 2K1C
surgery, the immunostaining of Cx40 (upper panels) was increased between the aortic EC of WT, but not of
Cx37/mice. Analogous changes were seen with regard to the immunostaining of Cx43 (middle panels)
between the SMC of the media. The immunostaining of Cx37 (lower panels) increased in the aortic media of
WT mice after the 2K1C surgery. L indicates lumen; M, media; Bar=20 lm. 2K1C indicates 2-kidney, 1-clip;
Cx37, Connexin37; Cx40, Connexin40; Cx43, Connexin43; Cx45, Connexin45; EC, endothelial cells; Sham,
sham-operated controls; SMC, smooth muscle cells; WT, wild type.
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remains to be fully elucidated. Although the bradykinin/NO/
cGMP vasodilator cascade is the main downstream pathway
responsible for the AT2R-mediated vasodepressor effect, we
did not observe altered aortic levels of eNOS and P-eNOS in
Cx37/ mice. In contrast, we found that Cx37/ mice
displayed an increased expression of the transcripts coding
for SHP-1 (Ptpn6), an important protein tyrosine phosphatase
downstream of AT2R and known to induce an SLK-mediated
RhoA phosphorylation, which inhibits RhoA-dependent arterial
contraction and promotes vasodilation.26 Accordingly, we also
found that the phosphorylation-dependent activation of the
myosin light chain 2 (MLC2), which is responsible for SMC
contraction in arteries, was not induced by Ang II in the
aortas of Cx37/ mice. Consistent with these results, we
further document that, after an Ang II stimulation, loss of
Cx37 altered the phosphorylation of ERK and AKT, 2 other
main downstream targets of AT1 receptors. Other proteins
may be involved in the dysregulation of the Ang II pathway,
inasmuch as we also found that loss of Cx37 increased the
mRNA expression of CNSKR1, the connector enhancer of
kinase suppressor of RAS 1, and of glutamyl aminopeptidase
A. Full validation of this conclusion now calls for further
experiments (eg, in the presence of antagonists and agonists
of the AT2 receptors). Similar experiments could similarly
target AT1 receptors to exclude a plausible alteration in their
sensitivity.
Figure 9. Continued
Figure 10. Loss of Cx37 did not alter the expression and activation of aortic eNOS. Western blots
showed similar levels of the eNOS protein (A) and of its activated, phosphorylated form (B) in the aortas of
all groups of mice. WT sham N=21; Cx37/ sham N=15; WT 2K1C N=17; Cx37/ 2K1C N=15. Results
are means+SEM. Statistical analysis was performed using 2-way ANOVA. Cx37 indicates Connexin37;
2K1C, 2-kidney, 1-clip; eNOS, endothelial nitric oxide synthase; Sham, sham-operated controls; WT, wild
type.
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Eventually, our data also revealed that loss of Cx37 is
associated with a signiﬁcant, selective increase in the
expression of Cx43 in SMC. This connexin allows for the
rapid diffusion of calcium-dependent contraction waves
between SMCs, modulating the vasomotor tone16,17 which,
in turn, is key for the development and maintenance of renin-
and Ang II-dependent hypertension.6,7,9,14,23,33 The speciﬁc
role that may be played by this connexin in the context of
Cx37/ mice exposed to hypertensive conditions remains
to be elucidated in future studies. Even though the expression
of Cx37, Cx43, and Cx405,6,8,9,12,47 is usually coordinated, a
contribution of the latter connexin appears unlikely in this
context, inasmuch as Cx40 is not expressed in the SMCs of
either normotensive or hypertensive mice,3,6,7,9,10,14 and its
vascular levels were not altered after loss of Cx37/.8
In summary, our ﬁndings document that loss of Cx37 partly
protects against the development of Ang II-dependent hyper-
tension, because of a selective increase in the expression of
AT2R and of some of the downstream effectors involved in the
signaling elicited by this form of Ang II receptors, notably SHP-
1. Even though the molecular mechanism whereby the loss of
Cx37 induces these alterations remains to be fully unraveled,
these ﬁndings highlight a so far unsuspected, speciﬁc role of
Cx37 in the control of the Ang II signaling pathway, setting the
ﬁrst, obligatory in vivo basis to now envisage further analyses
to ﬁne-tune the mechanistic scenario drafted here.
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